Axel Behrens

Axel Behrens

Auto-generated profile, based on publicly available information

Axel Behrens

Adult Stem Cell Laboratory, The Francis Crick Institute, London, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Neuron
Verified
Journal Article
Open access
PAPeter J. Arthur-Farraj
Peter J. Arthur-Farraj
MLMorwena Latouche
Morwena Latouche
DWDaniel K. Wilton
Daniel K. Wilton
SQSusanne Quintes
Susanne Quintes
ECElodie Chabrol
Elodie Chabrol
KJKristján R. Jessen
Kristján R. Jessen
The radical response of peripheral nerves to injury (Wallerian degeneration) is the cornerstone of nerve repair. We show that activation of the transcription factor c-Jun in Schwann cells is a global regulator of Wallerian degeneration. c-Jun governs major aspects of the injury response, determines the expression of trophic factors, adhesion molecules, the formation of regeneration tracks and myelin clearance and controls the distinctive regenerative potential of peripheral nerves. A key function of c-Jun is the activation of a repair program in Schwann cells and the creation of a cell specialized to support regeneration. We show that absence of c-Jun results in the formation of a dysfunctional repair cell, striking failure of functional recovery, and neuronal death. We conclude that a single glial transcription factor is essential for restoration of damaged nerves, acting to control the transdifferentiation of myelin and Remak Schwann cells to dedicated repair cells in damaged tissue.

27 February 2013 in Nature
Verified
Journal Article
Open access
PDF file
RBRebecca A. Burrell
Rebecca A. Burrell
SMSarah E. McClelland
Sarah E. McClelland
DEDavid Endesfelder
David Endesfelder
PGPetra Groth
Petra Groth
MWMarie-Christine Weller
Marie-Christine Weller
CSCharles Swanton
Charles Swanton
A mechanism to explain chromosomal instability (CIN) in colorectal cancer is demonstrated; three new CIN-suppressor genes (PIGN, MEX3C and ZNF516) encoded on chromosome 18q are identified, the loss of which leads to DNA replication stress, resulting in structural and numerical chromosome segregation errors, which are shown to be identical to phenotypes seen in CIN cells. Chromosomal instability (CIN) occurs in most solid tumours and is associated with poor prognosis and drug resistance. This study demonstrates a link between CIN in colorectal cancer and the loss of a region on chromosome 18q. The authors identify three previously unknown CIN-suppressor genes in this region that, when lost, lead to replication stress resulting in structural and numerical chromosome segregation errors. Supplementing tumour cell lines with nucleosides alleviates replication-associated damage, limits chromosome segregation errors after CIN-suppressor gene silencing and attenuates segregation errors and DNA damage in CIN+ cells. These findings point to a genetic mechanism — distinct from mitotic defects — that causes chromosome instability in colorectal tumours and that might be pharmacologically reversible. Cancer chromosomal instability (CIN) results in an increased rate of change of chromosome number and structure and generates intratumour heterogeneity1,2. CIN is observed in most solid tumours and is associated with both poor prognosis and drug resistance3,4. Understanding a mechanistic basis for CIN is therefore paramount. Here we find evidence for impaired replication fork progression and increased DNA replication stress in CIN+ colorectal cancer (CRC) cells relative to CIN− CRC cells, with structural chromosome abnormalities precipitating chromosome missegregation in mitosis. We identify three new CIN-suppressor genes (PIGN (also known as MCD4), MEX3C (RKHD2) and ZNF516 (KIAA0222)) encoded on chromosome 18q that are subject to frequent copy number loss in CIN+CRC. Chromosome 18q loss was temporally associated with aneuploidy onset at the adenoma–carcinoma transition. CIN-suppressor gene silencing leads to DNA replication stress, structural chromosome abnormalities and chromosome missegregation. Supplementing cells with nucleosides, to alleviate replication-associated damage5, reduces the frequency of chromosome segregation errors after CIN-suppressor gene silencing, and attenuates segregation errors and DNA damage in CIN+ cells. These data implicate a central role for replication stress in the generation of structural and numerical CIN, which may inform new therapeutic approaches to limit intratumour heterogeneity.

3 July 2024 in Nature
Verified
Journal Article
Open access
PDF file
HCHengxing Chen
Hengxing Chen
YLYun Li
Yun Li
HLHuafu Li
Huafu Li
XCXiancong Chen
Xiancong Chen
HFHuafeng Fu
Huafeng Fu
GWGuangxi Wang Wang
Guangxi Wang Wang
The Warburg effect is a hallmark of cancer that refers to the preference of cancer cells to metabolize glucose anaerobically rather than aerobically1,2. This results in substantial accumulation of lacate, the end product of anaerobic glycolysis, in cancer cells3. However, how cancer metabolism affects chemotherapy response and DNA repair in general remains incompletely understood. Here we report that lactate-driven lactylation of NBS1 promotes homologous recombination (HR)-mediated DNA repair. Lactylation of NBS1 at lysine 388 (K388) is essential for MRE11–RAD50–NBS1 (MRN) complex formation and the accumulation of HR repair proteins at the sites of DNA double-strand breaks. Furthermore, we identify TIP60 as the NBS1 lysine lactyltransferase and the ‘writer’ of NBS1 K388 lactylation, and HDAC3 as the NBS1 de-lactylase. High levels of NBS1 K388 lactylation predict poor patient outcome of neoadjuvant chemotherapy, and lactate reduction using either genetic depletion of lactate dehydrogenase A (LDHA) or stiripentol, a lactate dehydrogenase A inhibitor used clinically for anti-epileptic treatment, inhibited NBS1 K388 lactylation, decreased DNA repair efficacy and overcame resistance to chemotherapy. In summary, our work identifies NBS1 lactylation as a critical mechanism for genome stability that contributes to chemotherapy resistance and identifies inhibition of lactate production as a promising therapeutic cancer strategy.

1 March 1999 in Nature Genetics
Verified
Journal Article
Closed access
ABAxel Behrens
Axel Behrens
MSMaria Sibilia
Maria Sibilia
EWErwin F. Wagner
Erwin F. Wagner

1 July 2004 in Neuron
Verified
Journal Article
Closed access
GRGennadij Raivich
Gennadij Raivich
MBMarion Bohatschek
Marion Bohatschek
CCClive Da Costa
Clive Da Costa
OIOsuke Iwata
Osuke Iwata
MGMatthias Galiano
Matthias Galiano
ABAxel Behrens
Axel Behrens

19 May 2008 in Journal of Cell Biology
Verified
Journal Article
Open access
DPDavid B. Parkinson
David B. Parkinson
ABAmbily Bhaskaran
Ambily Bhaskaran
PAPeter Arthur-Farraj
Peter Arthur-Farraj
LNLuke A. Noon
Luke A. Noon
AWAshwin Woodhoo
Ashwin Woodhoo
KJKristján R. Jessen
Kristján R. Jessen
Schwann cell myelination depends on Krox-20/Egr2 and other promyelin transcription factors that are activated by axonal signals and control the generation of myelin-forming cells. Myelin-forming cells remain remarkably plastic and can revert to the immature phenotype, a process which is seen in injured nerves and demyelinating neuropathies. We report that c-Jun is an important regulator of this plasticity. At physiological levels, c-Jun inhibits myelin gene activation by Krox-20 or cyclic adenosine monophosphate. c-Jun also drives myelinating cells back to the immature state in transected nerves in vivo. Enforced c-Jun expression inhibits myelination in cocultures. Furthermore, c-Jun and Krox-20 show a cross-antagonistic functional relationship. c-Jun therefore negatively regulates the myelinating Schwann cell phenotype, representing a signal that functionally stands in opposition to the promyelin transcription factors. Negative regulation of myelination is likely to have significant implications for three areas of Schwann cell biology: the molecular analysis of plasticity, demyelinating pathologies, and the response of peripheral nerves to injury.